Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Submitted by
admin
on August 10, 2017 - 6:58pm
Source:
Fierce Pharma
News Tags:
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Headline:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Do Not Allow Advertisers to Use My Personal information
